DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60  years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma

ConclusionGCB DLBCL, younger patients, and high-risk patients, but not DEL patients, may benefit from continuous-infusion DA-EPOCH-R regimen.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research